[Correction of androgen deficiency in elderly patients]

Area of Science:

• Endocrinology
• Geriatrics
• Cardiovascular Medicine

Context:

• Androgen deficiency, characterized by declining testosterone levels starting around age 30-40, is increasingly recognized in aging populations.
• This deficiency is associated with a spectrum of age-related diseases, including cardiovascular conditions, obesity, and osteoporosis.
• The full implications and management of age-related androgen deficiency remain areas for continued investigation.

Purpose:

• To review the association between age-related androgen deficiency and various health conditions.
• To highlight the impact of declining testosterone on cardiovascular health and metabolic processes.
• To explore the potential benefits of androgen replacement therapy in managing these conditions.

Summary:

• Testosterone levels naturally decline with age, leading to androgen deficiency (hypogonadism) in men.
• This deficiency is correlated with increased risks of cardiovascular disease, metabolic syndrome (obesity, diabetes, dyslipidemia), and osteoporosis.
• Low testosterone is implicated in atherosclerosis, reduced fibrinolysis, and insulin resistance.

Impact:

• Understanding age-related androgen deficiency is crucial for addressing prevalent health concerns in aging men.
• Early identification and management may mitigate the risk of cardiovascular events and mortality.
• Physiological androgen replacement may offer therapeutic benefits for metabolic disturbances and disease progression.